Bloomberg -- Researchers canceled a study in Africa to see whether Gilead Science Inc.’s Truvada pill would help prevent infection from HIV, after finding no benefit by the people taking the medicine midway through the trial. Of the 56 women in the trial who contracted HIV, half were taking Truvada and half were on a placebo pill, according to a statement by FHI, a nonprofit global health group that sponsored the study. The trial of 3,902 women was halted after an independent data monitoring committee advised that it would be “highly unlikely to be able” to show Truvada’s effectiveness in preventing HIV infection in the study population, FHI said.
